Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $42.83 Consensus PT from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given an average rating of “Buy” by the six brokerages that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $42.83.

Several equities analysts have recently weighed in on DNTH shares. Stifel Nicolaus assumed coverage on Dianthus Therapeutics in a report on Thursday, February 15th. They set a “buy” rating and a $44.00 price target for the company. Raymond James lifted their target price on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a report on Thursday, April 18th. Wedbush increased their price target on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Jefferies Financial Group boosted their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 22nd. Finally, HC Wainwright began coverage on Dianthus Therapeutics in a research note on Thursday, May 16th. They set a “buy” rating and a $40.00 target price on the stock.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC purchased a new stake in Dianthus Therapeutics during the third quarter valued at $28,961,000. Acadian Asset Management LLC bought a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $303,000. Atlas Venture Life Science Advisors LLC purchased a new position in shares of Dianthus Therapeutics in the third quarter worth approximately $3,240,000. Avidity Partners Management LP purchased a new position in shares of Dianthus Therapeutics in the third quarter worth approximately $16,644,000. Finally, Laurion Capital Management LP purchased a new stake in Dianthus Therapeutics during the third quarter valued at approximately $497,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $23.05 on Thursday. The firm has a market capitalization of $676.52 million, a P/E ratio of -3.95 and a beta of 1.77. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77. The company’s 50-day simple moving average is $25.50 and its 200 day simple moving average is $19.18.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.40. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.73 million. On average, equities research analysts expect that Dianthus Therapeutics will post -2.16 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.